29.40
+0.41%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Hubei Jumpcan Pharmaceutical Co
Its shares trade on Shanghai under the ticker 600566.SS. It has been listed since 22 August 2001. In the fiscal year to 31 December 2025, it reported revenue of CN¥6.22bn and net income of CN¥1.78bn. At that date it held total assets of CN¥17.70bn and shareholders' equity of CN¥14.61bn.
Hubei Jumpcan Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of drugs. The company is headquartered in Taizhou, Jiangsu. The company went IPO on 2001-08-22. The firm's products include heat-clearing and detoxifying series, digestive system series, pediatric series, breathing series, cardiovascular series and gynecology series. Its pharmaceuticals consist of tablets, mixtures, injections, capsules, granules and sprays, among others. The firm mainly distributes its products within domestic markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 22 Aug 2001
- Employees
- 5,025
- Website
- jumpcan.com ↗
Leadership
Pay as last reported
- Mr. Longxiang CaoChairman of the Board, since 2017CN¥4.5m
- Mr. Fei CaoVice Chairman of the Board, General Manager, since 2014CN¥3.0m
- Mr. Hongquan YanChief Financial Officer, Deputy General ManagerCN¥1.7m
- Mr. Wenzheng ShiChief Human Resource OfficerCN¥1.2m
- Mr. Wei CaoDeputy General Manager, Secretary of the Board, Director, since 2018CN¥2.7m
- Mr. Qihua ZhouDeputy General ManagerCN¥1.6m
- Mr. Qurong HuangDirector, since 2014CN¥2.0m
- Mr. Chaojun LuIndependent DirectorCN¥120,000
- Mr. Yuhai YangIndependent DirectorCN¥120,000
- Mr. Hong YaoIndependent DirectorCN¥120,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 34
- Environment
- 34
- Social
- 33
- Governance
- 34
- Women in the workforce
- 48.8%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Hubei Jumpcan Pharmaceutical employs 5,025 full-time employees in Taizhou, Jiangsu.
- The company produces heat-clearing and detoxifying series for domestic markets.
- Hubei Jumpcan's product range includes cardiovascular and pediatric series.
Weaknesses
- The firm's products are distributed only within domestic markets in China.
- Hubei Jumpcan has no international presence beyond China's borders.
- The company's IPO was listed on 22 August 2001, showing limited market expansion.
Opportunities
- Expanding into international markets could increase Hubei Jumpcan's global reach.
- Growing demand for pharmaceuticals in China offers new market opportunities.
- The company can leverage its domestic market success to enter new segments.
Threats
- Competition from domestic pharmaceutical companies in China is intense.
- Regulatory changes in China's pharmaceutical sector could impact operations.
- Hubei Jumpcan's reliance on domestic markets poses a risk to growth.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.